Published in Gut on April 01, 1998
Neutrophil derived human S100A12 (EN-RAGE) is strongly expressed during chronic active inflammatory bowel disease. Gut (2003) 2.39
Selective granulocyte and monocyte adsorptive apheresis as a first-line treatment for steroid naïve patients with active ulcerative colitis: a prospective uncontrolled study. Dig Dis Sci (2004) 1.92
Down-regulation of interferon-gamma parallels clinical response to selective leukocyte apheresis in patients with inflammatory bowel disease: a 12-month follow-up study. Int J Colorectal Dis (2006) 1.53
Neuronal guidance molecule netrin-1 attenuates inflammatory cell trafficking during acute experimental colitis. Gut (2011) 1.39
Clinical value of fecal calprotectin in determining disease activity of ulcerative colitis. World J Gastroenterol (2008) 1.14
Imbalance between interleukin-1 agonists and antagonists: relationship to severity of inflammatory bowel disease. Clin Exp Immunol (2004) 1.14
Relationship between fecal calprotectin, intestinal inflammation, and peripheral blood neutrophils in patients with active ulcerative colitis. Dig Dis Sci (2004) 1.10
Future biologic targets for IBD: potentials and pitfalls. Nat Rev Gastroenterol Hepatol (2010) 1.06
Electroacupuncture and moxibustion promote neutrophil apoptosis and improve ulcerative colitis in rats. Dig Dis Sci (2007) 1.04
In vivo B1 kinin-receptor upregulation. Evidence for involvement of protein kinases and nuclear factor kappaB pathways. Br J Pharmacol (1999) 1.03
Cytapheresis as a Non-Pharmacological Therapy for Inflammatory Bowel Disease. Transfus Med Hemother (2007) 1.02
A retrospective search for predictors of clinical response to selective granulocyte and monocyte apheresis in patients with ulcerative colitis. Dig Dis Sci (2006) 1.02
Complex role for the immune system in initiation and progression of pancreatic cancer. World J Gastroenterol (2014) 1.00
Demonstration of low-regulatory CD25High+CD4+ and high-pro-inflammatory CD28-CD4+ T-Cell subsets in patients with ulcerative colitis: modified by selective granulocyte and monocyte adsorption apheresis. Dig Dis Sci (2007) 0.95
Induction of CD36 and thrombospondin-1 in macrophages by hypoxia-inducible factor 1 and its relevance in the inflammatory process. PLoS One (2012) 0.95
The mode of actions of the Adacolumn therapeutic leucocytapheresis in patients with inflammatory bowel disease: a concise review. Clin Exp Immunol (2010) 0.94
Effects of adacolumn selective leukocytapheresis on plasma cytokines during active disease in patients with active ulcerative colitis. World J Gastroenterol (2006) 0.90
Positions of selective leukocytapheresis in the medical therapy of ulcerative colitis. World J Gastroenterol (2006) 0.90
Serum calprotectin levels correlate with biochemical and histological markers of disease activity in TNBS colitis. Cell Immunol (2013) 0.90
Protective role of Akt2 in Salmonella enterica serovar typhimurium-induced gastroenterocolitis. Infect Immun (2011) 0.86
Long-term follow-up with Granulocyte and Monocyte Apheresis re-treatment in patients with chronically active inflammatory bowel disease. BMC Gastroenterol (2010) 0.86
Treating inflammatory bowel disease by adsorptive leucocytapheresis: a desire to treat without drugs. World J Gastroenterol (2014) 0.86
The efficacy and safety of selective leukocytapheresis in the treatment of ulcerative colitis: a meta-analysis. Int J Colorectal Dis (2011) 0.86
Dynamics of a cytokine storm. PLoS One (2012) 0.85
Adacolumn selective leukocyte adsorption apheresis in patients with active ulcerative colitis: clinical efficacy, effects on plasma IL-8, and expression of Toll-like receptor 2 on granulocytes. Dig Dis Sci (2007) 0.85
Decrease of reactive-oxygen-producing granulocytes and release of IL-10 into the peripheral blood following leukocytapheresis in patients with active ulcerative colitis. World J Gastroenterol (2005) 0.85
Activation of signal-transducer and activator of transcription 1 (STAT1) in pouchitis. Clin Exp Immunol (2001) 0.83
Oxidative stress, inflammation and neutrophil superoxide release in patients with Crohn's disease: distinction between active and non-active disease. Dig Dis Sci (2008) 0.83
Colonic inflammation in mice is improved by cigarette smoke through iNKT cells recruitment. PLoS One (2013) 0.81
Inflammation modulates fibronectin isoform expression in colonic lamina propria fibroblasts (CLPF). Int J Colorectal Dis (2008) 0.81
Treatment of children and adolescents with ulcerative colitis by adsorptive depletion of myeloid lineage leucocytes as monotherapy or in combination with low dose prednisolone after failure of first-line medications. BMC Gastroenterol (2013) 0.81
Small bowel review: normal physiology part 2. Dig Dis Sci (2001) 0.81
Cytapheresis in patients with severe ulcerative colitis after failure of intravenous corticosteroid: a long-term retrospective cohort study. Gut Liver (2009) 0.79
Efficacy, safety and cost analyses in ulcerative colitis patients undergoing granulocyte and monocyte adsorption or receiving prednisolone. BMC Gastroenterol (2013) 0.78
Enhanced production of early lineages of monocytic and granulocytic cells in mice with colitis. Proc Natl Acad Sci U S A (2012) 0.78
Deficiency of Nuclear Receptor Nur77 Aggravates Mouse Experimental Colitis by Increased NFκB Activity in Macrophages. PLoS One (2015) 0.78
Genetic update on inflammatory factors in ulcerative colitis: Review of the current literature. World J Gastrointest Pathophysiol (2014) 0.76
Leukocyte apheresis in the management of ulcerative colitis. Saudi J Gastroenterol (2009) 0.75
Relationship between genotype and phenotype of flagellin C in Salmonella. World J Gastroenterol (2001) 0.75
LPS-Stimulated Whole Blood Cytokine Production Is Not Related to Disease Behavior in Patients with Quiescent Crohn's Disease. PLoS One (2015) 0.75
A commensal Bifidobacterium longum strain improves gluten-related immunopathology in mice through expression of a serine protease inhibitor. Appl Environ Microbiol (2017) 0.75
Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem (1987) 281.19
The NF-kappa B and I kappa B proteins: new discoveries and insights. Annu Rev Immunol (1996) 22.30
Cytochemical identification of monocytes and granulocytes. Am J Clin Pathol (1971) 20.35
Interleukin 10(IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes. J Exp Med (1991) 16.81
Quantitation of mRNA by the polymerase chain reaction. Proc Natl Acad Sci U S A (1989) 15.69
Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. Gastroenterology (1976) 15.65
IL-10 inhibits cytokine production by activated macrophages. J Immunol (1991) 13.13
NF-kappa B: a pleiotropic mediator of inducible and tissue-specific gene control. Cell (1989) 11.19
Interleukin-1 and interleukin-1 antagonism. Blood (1991) 7.67
Isolation and expression of human cytokine synthesis inhibitory factor cDNA clones: homology to Epstein-Barr virus open reading frame BCRFI. Proc Natl Acad Sci U S A (1991) 5.02
Enhanced secretion of tumour necrosis factor-alpha, IL-6, and IL-1 beta by isolated lamina propria mononuclear cells from patients with ulcerative colitis and Crohn's disease. Clin Exp Immunol (1993) 4.68
Enhanced production of interleukin 1-beta by mononuclear cells isolated from mucosa with active ulcerative colitis of Crohn's disease. Gut (1989) 4.59
The production of cytokines by polymorphonuclear neutrophils. Immunol Today (1995) 4.27
Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial. BMJ (1989) 4.13
Modulation of granulocyte survival and programmed cell death by cytokines and bacterial products. Blood (1992) 4.11
Priming of neutrophils for enhanced release of oxygen metabolites by bacterial lipopolysaccharide. Evidence for increased activity of the superoxide-producing enzyme. J Exp Med (1984) 3.79
Tumour necrosis factor-alpha and interferon-gamma production measured at the single cell level in normal and inflamed human intestine. Clin Exp Immunol (1990) 3.54
Adhesion molecules and inflammatory injury. FASEB J (1994) 3.53
The role of interleukin-1 in disease. N Engl J Med (1993) 3.45
Role of interleukin 1 in inflammatory bowel disease--enhanced production during active disease. Gut (1990) 3.18
Cytokine messenger RNA profiles in inflammatory bowel disease mucosa detected by polymerase chain reaction amplification. Gastroenterology (1992) 3.04
Interleukin-10. Curr Opin Immunol (1992) 2.85
Tumor necrosis factor-alpha, interleukin-1 beta, and interleukin-6 expression in inflammatory bowel disease. Dig Dis Sci (1992) 2.47
Immunoregulatory role of interleukin 10 in patients with inflammatory bowel disease. Gastroenterology (1995) 2.38
Quantitative fecal indium 111-labeled leukocyte excretion in the assessment of disease in Crohn's disease. Gastroenterology (1983) 2.37
IL-10, T lymphocyte inhibitor of human blood cell production of IL-1 and tumor necrosis factor. J Immunol (1992) 2.09
Multiple doses of intravenous interleukin 10 in steroid-refractory Crohn's disease. Crohn's Disease Study Group. Gastroenterology (1997) 2.00
Cytokines in stools of children with inflammatory bowel disease or infective diarrhoea. J Clin Pathol (1993) 1.96
Neutrophil-mediated mucosal injury. Role of reactive oxygen metabolites. Dig Dis Sci (1988) 1.81
Expression of vascular adhesion molecules in inflammatory bowel disease. Gastroenterology (1992) 1.62
Expression of leukocyte adhesion molecules by mucosal mononuclear phagocytes in inflammatory bowel disease. Gastroenterology (1991) 1.62
The role of the mucosal immune system in inflammatory bowel disease. Gastroenterol Clin North Am (1992) 1.59
Enhanced mucosal cytokine production in inflammatory bowel disease. Gastroenterology (1992) 1.53
Interleukin 10 (IL-10) upregulates IL-1 receptor antagonist production from lipopolysaccharide-stimulated human polymorphonuclear leukocytes by delaying mRNA degradation. J Exp Med (1994) 1.48
Scintigraphic assessment of bowel involvement and disease activity in Crohn's disease using technetium 99m-hexamethyl propylene amine oxine as leukocyte label. Gastroenterology (1988) 1.35
Neutrophil mucosal involvement is accompanied by enhanced local production of interleukin-8 in ulcerative colitis. Gut (1993) 1.33
Phagocytosis of opsonized yeast induces tumor necrosis factor-alpha mRNA accumulation and protein release by human polymorphonuclear leukocytes. J Leukoc Biol (1991) 1.19
Increased neutrophil receptors for and response to the proinflammatory bacterial peptide formyl-methionyl-leucyl-phenylalanine in Crohn's disease. Gastroenterology (1989) 0.98
Inflammatory bowel disease is associated with increased mucosal levels of bactericidal/permeability-increasing protein. Gastroenterology (1996) 0.97
Faecal elastase reflects disease activity in active ulcerative colitis. Scand J Gastroenterol (1992) 0.95
Granulocyte migration in ulcerative colitis. Eur J Clin Invest (1985) 0.94
Analytical performances of commercial ELISA-kits for IL-2, IL-6 and TNF-alpha. A WHO study. Eur Cytokine Netw (1994) 0.93
Increased in vitro release of soluble interleukin 2 receptor by colonic lamina propria mononuclear cells in inflammatory bowel disease. Gut (1992) 0.90
Crohn's disease monocytes are primed for accentuated release of toxic oxygen metabolites. Gastroenterology (1993) 0.89
In vivo assessment of granulocyte migration to diseased bowel in Crohn's disease. Gut (1985) 0.85
Chemiluminescent response of neutrophils from patients with inflammatory bowel disease. Dig Dis Sci (1985) 0.83
Interleukin-10 decreases tyrosine phosphorylation of discrete lipopolysaccharide-induced phosphoproteins in human granulocytes. Biochem Biophys Res Commun (1995) 0.78
Chemiluminescence by polymorphonuclear leucocyte subpopulations in chronic inflammatory bowel disease. Influence of the cell separation procedure. Digestion (1990) 0.77
Enhanced superoxide anion release of normal neutrophil granulocytes primed with sera of patients with inactive inflammatory bowel disease. Z Gastroenterol (1995) 0.77
PMN-elastase in assessment of patients with inflammatory bowel disease. Dig Dis Sci (1993) 0.76
Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet (2002) 14.14
Association between insertion mutation in NOD2 gene and Crohn's disease in German and British populations. Lancet (2001) 7.27
Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet (2002) 5.48
Reduction in diversity of the colonic mucosa associated bacterial microflora in patients with active inflammatory bowel disease. Gut (2004) 5.32
Enhanced secretion of tumour necrosis factor-alpha, IL-6, and IL-1 beta by isolated lamina propria mononuclear cells from patients with ulcerative colitis and Crohn's disease. Clin Exp Immunol (1993) 4.68
European evidence based consensus on the diagnosis and management of Crohn's disease: current management. Gut (2006) 3.59
Intestinal permeability and the prediction of relapse in Crohn's disease. Lancet (1993) 3.42
The genetic basis for the association of the 8.1 ancestral haplotype (A1, B8, DR3) with multiple immunopathological diseases. Immunol Rev (1999) 3.21
[German guideline for diagnosis and management of idiopathic pulmonary fibrosis]. Pneumologie (2013) 3.03
Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis. Gut (2004) 3.01
A genomewide analysis provides evidence for novel linkages in inflammatory bowel disease in a large European cohort. Am J Hum Genet (1999) 2.88
The risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET consensus statement. Eur Respir J (2010) 2.56
Macrophage subpopulations in lamina propria of normal and inflamed colon and terminal ileum. Gut (1989) 2.44
Series of exon-skipping events in the elastic spring region of titin as the structural basis for myofibrillar elastic diversity. Circ Res (2000) 2.39
Modulation of human dendritic cell phenotype and function by probiotic bacteria. Gut (2004) 2.29
Tumour necrosis factor alpha and interleukin 1beta in relapse of Crohn's disease. Lancet (1999) 2.29
Impact on the composition of the faecal flora by a new probiotic preparation: preliminary data on maintenance treatment of patients with ulcerative colitis. Aliment Pharmacol Ther (1999) 2.26
Acute right-sided heart failure due to hemorrhage into a pericardial cyst. Ann Thorac Surg (1997) 2.24
Recombinant human interleukin 10 in the treatment of patients with mild to moderately active Crohn's disease. The Interleukin 10 Inflammatory Bowel Disease Cooperative Study Group. Gastroenterology (2000) 2.23
Adalimumab for the treatment of fistulas in patients with Crohn's disease. Gut (2009) 2.20
Genetic basis for increased intestinal permeability in families with Crohn's disease: role of CARD15 3020insC mutation? Gut (2005) 2.17
Recombinant erythropoietin for the treatment of anemia in inflammatory bowel disease. N Engl J Med (1996) 2.16
Association between intraepithelial Escherichia coli and colorectal cancer. Gastroenterology (1998) 2.15
TMEM132D, a new candidate for anxiety phenotypes: evidence from human and mouse studies. Mol Psychiatry (2010) 2.00
European evidence-based Consensus on the diagnosis and management of ulcerative colitis: Definitions and diagnosis. J Crohns Colitis (2008) 1.99
Bacteria as the cause of ulcerative colitis. Gut (2001) 1.96
Infliximab in moderately severe glucocorticoid resistant ulcerative colitis: a randomised controlled trial. Gut (2003) 1.95
Examination of the current top candidate genes for AD in a genome-wide association study. Mol Psychiatry (2009) 1.89
Definition of polymorphisms and haplotypes in the interleukin-12B gene: association with IL-12 production but not with Crohn's disease. Genes Immun (2004) 1.89
I-band titin in cardiac muscle is a three-element molecular spring and is critical for maintaining thin filament structure. J Cell Biol (1999) 1.88
European evidence based consensus on the diagnosis and management of Crohn's disease: special situations. Gut (2006) 1.87
Photodynamic therapy of nonresectable cholangiocarcinoma. Gastroenterology (1998) 1.86
Postural dependency of the cerebral venous outflow. Lancet (2000) 1.81
Small bowel involvement in Crohn's disease: a prospective comparison of wireless capsule endoscopy and computed tomography enteroclysis. Gut (2005) 1.78
Randomised trial of once- or twice-daily MMX mesalazine for maintenance of remission in ulcerative colitis. Gut (2008) 1.75
Genetic analysis of inflammatory bowel disease in a large European cohort supports linkage to chromosomes 12 and 16. Gastroenterology (1998) 1.73
Predictors of PTSD in injured trauma survivors: a prospective study. Am J Psychiatry (1996) 1.68
Association between genetic variation in a region on chromosome 11 and schizophrenia in large samples from Europe. Mol Psychiatry (2011) 1.65
COGENT (COlorectal cancer GENeTics): an international consortium to study the role of polymorphic variation on the risk of colorectal cancer. Br J Cancer (2009) 1.62
Increased expression of IP-10, IL-8, MCP-1, and MCP-3 in ulcerative colitis. Am J Pathol (1999) 1.62
An integrated system for high throughput TaqMan based SNP genotyping. Bioinformatics (2001) 1.61
Interaction of probiotic Lactobacillus and Bifidobacterium strains with human intestinal epithelial cells: adhesion properties, competition against enteropathogens and modulation of IL-8 production. Int J Food Microbiol (2008) 1.61
Killer-cell immunoglobulin-like receptor (KIR) nomenclature report, 2002. Tissue Antigens (2003) 1.60
Steroid treatment in active Crohn's disease: a comparison between two regimens of different duration. Aliment Pharmacol Ther (1994) 1.59
Titin-actin interaction in mouse myocardium: passive tension modulation and its regulation by calcium/S100A1. Biophys J (2001) 1.59
Immunization of cancer patients with autologous cancer-derived heat shock protein gp96 preparations: a pilot study. Int J Cancer (2000) 1.58
Linkage of inflammatory bowel disease to human chromosome 6p. Am J Hum Genet (1999) 1.57
Association of inflammatory bowel disease risk loci with sarcoidosis, and its acute and chronic subphenotypes. Eur Respir J (2010) 1.55
Enhancement of macrophage candidacidal activity by interferon-gamma. Increased phagocytosis, killing, and calcium signal mediated by a decreased number of mannose receptors. J Clin Invest (1993) 1.50
Controlled study using wireless capsule endoscopy for the evaluation of the small intestine in chronic refractory pouchitis. Aliment Pharmacol Ther (2007) 1.49
Macroscopic appearance of intestinal angiodysplasias under antiangiogenic treatment with thalidomide. Endoscopy (2006) 1.49
Olsalazine versus mesalazine in the treatment of mild to moderate ulcerative colitis. Aliment Pharmacol Ther (1998) 1.47
Keratin 8 Y54H and G62C mutations are not associated with inflammatory bowel disease. Dig Liver Dis (2004) 1.45
A comparative study on demographic, hematological, and cytogenetic findings and prognosis in acute myeloid leukemia with and without leukemia cutis. Ann Hematol (2002) 1.44
Beclomethasone dipropionate versus mesalazine in distal ulcerative colitis: a multicenter, randomized, double-blind study. Dig Liver Dis (2007) 1.43
Long-term safety and efficacy of certolizumab pegol in the treatment of Crohn's disease: 7-year results from the PRECiSE 3 study. Aliment Pharmacol Ther (2014) 1.43
Endoscopic ultrasound of the colon for the differentiation of Crohn's disease and ulcerative colitis in comparison with healthy controls. Aliment Pharmacol Ther (2014) 1.43
Expression of cytokines, inducible nitric oxide synthase, and matrix metalloproteinases in pouchitis: effects of probiotic treatment. Am J Gastroenterol (2001) 1.43
Genome-wide survey implicates the influence of copy number variants (CNVs) in the development of early-onset bipolar disorder. Mol Psychiatry (2011) 1.43
Introduction of the lung allocation score in Germany. Am J Transplant (2014) 1.42
An analysis of the safety of the single dose, two drug regimens used in programmes to eliminate lymphatic filariasis. Parasitology (2000) 1.42
Treatment of Crohn's disease with recombinant human interleukin 10 induces the proinflammatory cytokine interferon gamma. Gut (2002) 1.41
Review article: the management of refractory Crohn's disease. Aliment Pharmacol Ther (2002) 1.41
Safety and efficacy of repeated shockwave lithotripsy of gallstones with and without adjuvant bile acid therapy. Gastroenterology (1997) 1.41
Probiotics in inflammatory bowel disease: new insight to pathogenesis or a possible therapeutic alternative? Gastroenterology (1999) 1.40
Inferior subluxation of the humeral head: the drooping shoulder. Radiology (1971) 1.39
Human airway smooth muscle cells express and release RANTES in response to T helper 1 cytokines: regulation by T helper 2 cytokines and corticosteroids. J Immunol (1997) 1.38
[Food-dependent Cushing syndrome of long standing with mild clinical features]. Dtsch Med Wochenschr (2000) 1.38
Identification and biochemical characterization of Arabidopsis thaliana sulfite oxidase. A new player in plant sulfur metabolism. J Biol Chem (2001) 1.38
ESPEN Guidelines on Enteral Nutrition: Geriatrics. Clin Nutr (2006) 1.37
Bacterial and fungal microbiota in relation to probiotic therapy (VSL#3) in pouchitis. Gut (2006) 1.36
Diagnostic yield of wireless capsule enteroscopy in comparison with computed tomography enteroclysis. Endoscopy (2003) 1.34
Antibiotic treatment of Crohn's disease: results of a multicentre, double blind, randomized, placebo-controlled trial with rifaximin. Aliment Pharmacol Ther (2006) 1.33
Spectral oscillations of RR intervals in sleep apnoea/hypopnoea syndrome patients. Eur Respir J (2003) 1.33
Genetic analysis in Italian families with inflammatory bowel disease supports linkage to the IBD1 locus--a GISC study. Eur J Hum Genet (1999) 1.32
Interferon beta-1a in ulcerative colitis: a placebo controlled, randomised, dose escalating study. Gut (2003) 1.31
Randomized controlled trial of silymarin treatment in patients with cirrhosis of the liver. J Hepatol (1989) 1.30
Closed-head minimal traumatic brain injury produces long-term cognitive deficits in mice. Neuroscience (2003) 1.29
Rifaximin in patients with moderate or severe ulcerative colitis refractory to steroid-treatment: a double-blind, placebo-controlled trial. Dig Dis Sci (1999) 1.29
Evaluation of AGR2 and AGR3 as candidate genes for inflammatory bowel disease. Genes Immun (2006) 1.26
Higher expression of glucocorticoid receptor in peripheral mononuclear cells in inflammatory bowel disease. Am J Gastroenterol (2000) 1.26
Preactivated peripheral blood monocytes in patients with essential hypertension. Hypertension (1999) 1.26
Genetic control of suppressor lymphocyte function in myasthenia gravis: relationship of impaired suppressor function to HLA-B8/DRW3 and cold reactive lymphocytotoxic antibodies. Clin Immunol Immunopathol (1979) 1.23
Fine mapping of the chromosome 3p susceptibility locus in inflammatory bowel disease. Gut (2001) 1.23
Does passage of a patency capsule indicate small-bowel patency? A prospective clinical trial? Endoscopy (2005) 1.22
Bone mineralization as studied by small-angle x-ray scattering. Connect Tissue Res (1996) 1.21
Physiologic responses to loud tones in Israeli patients with posttraumatic stress disorder. Arch Gen Psychiatry (1992) 1.20
A randomised placebo controlled trial of pegylated interferon alpha in active ulcerative colitis. Gut (2003) 1.19
[Clinical practice guideline on diagnosis and treatment of Crohn's disease]. Z Gastroenterol (2008) 1.19